Journal
INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY
Volume 27, Issue 4, Pages 363-369Publisher
SPRINGER INDIA
DOI: 10.1007/s12291-012-0225-8
Keywords
Diabetes mellitus; Glycemic control; HBA1c; Dyslipidemia; Metformin; Glibenclamide
Categories
Funding
- Addis Ababa University, Ethiopia
Ask authors/readers for more resources
The nature of the dyslipidemia associated with diabetes mellitus is complex and is the major risk factor for atherosclerosis and coronary artery disease. Aim of this study was to assess the effect of glycemic control, achieved by metformin, glibenclamide and insulin, on lipid profile in type 2 diabetic patients. One hundred and sixty-five type 2 diabetes mellitus patients were classified into good glycemic control (Group I) and poor glycemic control (Group II) on the basis of their blood HbA1c values. The Group II was characterized with high serum triglyceride (190.46 +/- 15.20 mg/dl), total cholesterol (175.3 +/- 6.31 mg/dl) as well as high LDL-cholesterol (109.0 +/- 5.88 mg/dl). Significant correlations were evident between HbA1c and dyslipidemia, particularly serum TG (r = 0.28, P<0.05), and between HbA1c and total cholesterol (r = 0.310, P<0.05). Better glycemic control and improved dyslipidemia were observed in patients on combination therapy of metformin plus glibenclamide.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available